For purification and characterization of interferon alpha and cloning of the human interferon alpha gene and mass production of recombinant interferon alpha for cancer treatment and treatment of hepatitis C.
Dr. Goeddel is currently Managing Partner of The Column Group, a leading venture capital firm dedicated to creating the next generation of biotechnology companies. He co-founded Tularik Inc. in 1991, was Vice President of Research until 1996 and CEO from 1996 - 2004, when Tularik was acquired by Amgen. He served as Amgen’s first Senior Scientific Vice President until 2006. Prior to Tularik, he was the first scientist hired by Genentech, Inc. in 1978 and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.